Duchenne Muscular Dystrophy Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Duchenne Muscular Dystrophy Drugs Market Professional Survey Report 2019

Request for Sample of this report

Buy now

Table of Content

Executive Summary

1 Industry Overview of Duchenne Muscular Dystrophy Drugs

1.1 Definition of Duchenne Muscular Dystrophy Drugs
1.2 Duchenne Muscular Dystrophy Drugs Segment by Type
- 1.2.1 Global Duchenne Muscular Dystrophy Drugs Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Development & Drug Target
- 1.2.3 Mechanism of Action (MoA)
- 1.2.4 Route of Administration (RoA)
- 1.2.5 Molecule Type
1.3 Duchenne Muscular Dystrophy Drugs Segment by Applications
- 1.3.1 Global Duchenne Muscular Dystrophy Drugs Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals and Clinics
- 1.3.3 Medical Laboratories
- 1.3.4 Others
1.4 Global Duchenne Muscular Dystrophy Drugs Overall Market
- 1.4.1 Global Duchenne Muscular Dystrophy Drugs Revenue (2014-2025)
- 1.4.2 Global Duchenne Muscular Dystrophy Drugs Production (2014-2025)
- 1.4.3 North America Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.4 Europe Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.5 China Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.6 Japan Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.8 India Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy Drugs
2.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs
2.4 Industry Chain Structure of Duchenne Muscular Dystrophy Drugs

3 Development and Manufacturing Plants Analysis of Duchenne Muscular Dystrophy Drugs

3.1 Capacity and Commercial Production Date
3.2 Global Duchenne Muscular Dystrophy Drugs Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Duchenne Muscular Dystrophy Drugs
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

4.1 Duchenne Muscular Dystrophy Drugs Production and Capacity Analysis
4.2 Duchenne Muscular Dystrophy Drugs Revenue Analysis
4.3 Duchenne Muscular Dystrophy Drugs Price Analysis
4.4 Market Concentration Degree

5 Duchenne Muscular Dystrophy Drugs Regional Market Analysis

5.1 Duchenne Muscular Dystrophy Drugs Production by Regions
- 5.1.1 Global Duchenne Muscular Dystrophy Drugs Production by Regions
- 5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Regions
5.2 Duchenne Muscular Dystrophy Drugs Consumption by Regions
5.3 North America Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.3.1 North America Duchenne Muscular Dystrophy Drugs Production
- 5.3.2 North America Duchenne Muscular Dystrophy Drugs Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Duchenne Muscular Dystrophy Drugs Import and Export
5.4 Europe Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.4.1 Europe Duchenne Muscular Dystrophy Drugs Production
- 5.4.2 Europe Duchenne Muscular Dystrophy Drugs Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Duchenne Muscular Dystrophy Drugs Import and Export
5.5 China Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.5.1 China Duchenne Muscular Dystrophy Drugs Production
- 5.5.2 China Duchenne Muscular Dystrophy Drugs Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Duchenne Muscular Dystrophy Drugs Import and Export
5.6 Japan Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.6.1 Japan Duchenne Muscular Dystrophy Drugs Production
- 5.6.2 Japan Duchenne Muscular Dystrophy Drugs Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Duchenne Muscular Dystrophy Drugs Import and Export
5.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.7.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Production
- 5.7.2 Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Duchenne Muscular Dystrophy Drugs Import and Export
5.8 India Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.8.1 India Duchenne Muscular Dystrophy Drugs Production
- 5.8.2 India Duchenne Muscular Dystrophy Drugs Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Duchenne Muscular Dystrophy Drugs Import and Export

6 Duchenne Muscular Dystrophy Drugs Segment Market Analysis (by Type)

6.1 Global Duchenne Muscular Dystrophy Drugs Production by Type
6.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Type
6.3 Duchenne Muscular Dystrophy Drugs Price by Type

7 Duchenne Muscular Dystrophy Drugs Segment Market Analysis (by Application)

7.1 Global Duchenne Muscular Dystrophy Drugs Consumption by Application
7.2 Global Duchenne Muscular Dystrophy Drugs Consumption Market Share by Application (2014-2019)

8 Duchenne Muscular Dystrophy Drugs Major Manufacturers Analysis

9 Development Trend of Analysis of Duchenne Muscular Dystrophy Drugs Market

9.1 Global Duchenne Muscular Dystrophy Drugs Market Trend Analysis
- 9.1.1 Global Duchenne Muscular Dystrophy Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Duchenne Muscular Dystrophy Drugs Regional Market Trend
- 9.2.1 North America Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.2 Europe Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.3 China Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.4 Japan Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.5 Southeast Asia Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.6 India Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
9.3 Duchenne Muscular Dystrophy Drugs Market Trend (Product Type)
9.4 Duchenne Muscular Dystrophy Drugs Market Trend (Application)
10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
10.3 Duchenne Muscular Dystrophy Drugs Customers

11 Market Dynamics

11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion

13 Appendix

13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
13.3 Author List

Description

Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

The global Duchenne Muscular Dystrophy Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Duchenne Muscular Dystrophy Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Duchenne Muscular Dystrophy Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Duchenne Muscular Dystrophy Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Duchenne Muscular Dystrophy Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type

Segment by Application
Hospitals and Clinics
Medical Laboratories
Others